Supervision and approval of advanced therapy medicinal products in European and its inspirationsCHEN Yun, LI Shan-shan, SHAO Rong, ZHOU Bin1681-1690
Research on the interim fund for high-value innovative drugs:based on the empirical study of cancer drugs fund in englandDING Jin-xi, WU Yi-fei, LI Jia-ming, LI Wei1691-1696
Analysis of FDA inspection on pharmaceutical manufacturing industry in ChinaYAN Ruo-xi, CAO Yi, DONG Jiang-ping1697-1701
Considerations on the necessity of efficacy clinical trials for influenza vaccineLIU Bo, DENG Xia, WANG Yuan-zheng, YIN Xiao, SU Yao, ZHANG Yan, LI Ying-li, GAO Chen-yan, YANG Huan1702-1706
Considerations in bioequivalence study for potassium chloride sustained-release tabletsLIU Shu-jie, LI Min, MA Jing-yi, WANG Ke-zhan, YANG Jin-bo1707-1710
General considerations on the selection of relevant species for immune-oncology drugsGONG Xin-jiang, SHAO Xue, HUANG Fang-hua, CEN Xiao-bo, HU Xiao-min, WANG Hai-xue, WANG Qing-li1711-1716
Specific considerations in the implementation of S9 in ICH guideline in ChinaYE Xuan, ZHANG Min, YAN Li-ping, YU Bing, WANG Hai-xue1717-1722
Non-clinical research strategy for the treatment of fundus diseasesWANG Ruo-nan, QIAN Yi-min, SONG Shuo, LI Hua, MA Jing1723-1728
Research advances on bioactivity and pharmacological effects of chicoric acidWANG Yu-zhen, GAO Shuang, LI Ling-jun, ZHANG Li, SUN Yue, BO Fu-min1729-1733
Considerations on the clinical trials of mesenchymal stem cells for the treatment of novel coronavirus infected pneumonia in patientsGAO Jian-chao, WAN Zhi-hong, HUANG Yun-hong, WANG Hui-cheng, GAO Chen-yan1734-1737